At the news
? NEUTRALIMPACT 2/10 8-K filed Apr 27, 2026 at 16:06 ET
Abbott Laboratories filed an 8-K reporting the adoption of amended and restated bylaws effective April 24, 2026 (Item 5.03) and provided standard form equity award agreements under the 2026 Incentive Stock Program (Exhibits 10.23 and 10.18). No material financial data, officer changes, or shareholder vote results were disclosed. The filing is routine and has no immediate trading implications.
- Amended and restated bylaws adopted effective April 24, 2026.
- Non-Qualified Stock Option Agreement and Performance Restricted Stock Unit Agreement forms filed as exhibits (placeholder terms).
- No actual grant amounts, exercise prices, or performance targets disclosed.
- Shareholder votes occurred (Item 5.07) but results not provided in filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access